Practice Resources | Antiemetics Study Group
MASCC Antiemetic Guidelines
©MASCC, Multinational Association for Supportive Care in Cancer™ • All rights reserved worldwide.
MASCC/ESMO Antiemetic Guidelines
Organizing and Overall Meeting Chairs: Matti Aapro, MD, Richard J. Gralla, MD, Jørn Herrstedt, MD, DMSci, Alex Molassiotis, RN, PhD, Fausto Roila, MD for the ESMO/MASCC Guidelines Working Group.
The MASCC/ESMO Antiemetic Guidelines have been updated as of March, 2016. The revised guidelines are based on the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015, and have been endorsed by both MASCC and ESMO.
MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting: ESMO Clinical Practice Guidelines. F. Roila, A. Molassiotis, J. Herrstedt, M. Aapro, R. J. Gralla, E. Bruera, et al. On behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. Ann Oncol. 2016; 27(suppl 5):v119-v133, 2016.
The previous version of the Antiemetic Guidelines was based on the Consensus Guideline Meeting held in Perugia, Italy, June 2009.
Guideline Update for MASCC and ESMO in the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting: Results of the Perugia Consensus Conference. F. Roila, J. Herrstedt, M. Aapro, R. J. Gralla, L. H. Einhorn, E. Ballatori, et al. On behalf of the ESMO/MASCC Guidelines Working Group. Ann Oncol. 2010;21(suppl 5):v232-43.
The full-text versions of the 2016 MASCC/ESMO Consensus Recommendation papers from Supportive Care in Cancer (Vol. 27, Supplement 5, 2016), which reflect the conclusions of the 2015 Consensus Conference, are available, courtesy of MASCC and Springer.
The full-text versions of the 2010 MASCC/ESMO Antiemetic Guideline papers from Supportive Care in Cancer (Vol. 19, Supplement 1, March 2011) are also available courtesy of MASCC and Springer. These papers represent a detailed summary of the deliberations from the Consensus Guideline Meeting in Perugia, Italy, June 2009.
Download the Guidelines
English - Version 1.1 - Updated March 2016 | Guidelines-English | 2016 Guidelines-English (pptx)
Translations - Translation Policy • For more translation information please contact Anne Young at firstname.lastname@example.org
Arabic - Translated June 2010 - MASCC Guidelines Arabic
Translated by Bassam Estfan
Chinese - Translated April 2011 - MASCC Guidelines Chinese | MASCC Guidelines Chinese (ppt)
Translation provided by Shiyong Wang
French- Translated April 2012 - MASCC Guidelines French | MASCC Guidelines French (ppt)
German- Translated May 2016 - MASCC Guidelines German | MASCC Guidelines German (pptx)
Translation provided by ASORS
Greek - Translated November 2010 - MASCC Guidelines Greek | MASCC Guidelines Greek (pps)
Translated by Ourania Nicolatou-Galitis and Erofili Papadopoulou
Japanese Translation - Translated May 2016 - MASCC Guidelines Japanese | MASCC Guidelines Japanese (ppt)
Translated by Springer and reviewed by JASCC
Portuguese - Translated March 2011 - MASCC Guidelines Portuguese | MASCC Guidelines Portuguese (ppt)
Russian - Translated August 2011 - MASCC Guidelines Russian | MASCC Guidelines Russian (ppt)
Translated by Anton Snegovoy
Serbian - Translated April 2013 - MASCC Guidelines Serbian | MASCC Guidelines Serbian (ppt)
Translated by Snezana Bosnjak, Jelena Dimitrijevic and Ana Vujovic
Spanish - Translated August 2011 - MASCC Guidelines Spanish | MASCC Guidelines Spanish (ppt)
Translated by Alvaro Menendez
Turkish - Translated August 2010 - MASCC_Guidelines-Turkish | MASCC Guidelines Turkish (ppt)
Translated by Ahmet Sezer, Ali Ayberk Besen, Huseyin Abali
The following translations of the updated 2010 guidelines will be available soon.
Italian - Translated December 7, 2005 - MASCC Guidelines Italian | MASCC Guidelines Italian (ppt)
Translated by Dr. Garassina
Korean Translation - Translated December, 2008 - MASCC Guidelines-Korean
Thanks to Dr. Young Seon Hong for guideline translation
MASCC Endorsed Guideline Partnerships
Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting Due to Chemotherapy in Pediatric Cancer Patients
The Pediatric Oncology Group of Ontario (POGO) has published "Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting due to Chemotherapy in Pediatric Cancer Patients” (April 2014). This evidence-based guideline contains recommendations for optimizing control of anticipatory nausea and vomiting in children from 1 month to 18 years of age who are receiving chemotherapy. Recommendations for both pharmacological and nonpharmacological interventions are included. >> Read the Guideline *Disclaimer* The evidence used in formulating this guideline was rated as "low level" by the authors and much of it was derived from evidence in the adult population, rather than a pediatric population. While the conclusions have face validity, the strength of the recommendations is limited by a dearth of high-quality data. There remains a need for more studies in the pediatric population.
Acute AINV Guideline for Pediatric Cancer Patients
The Pediatric Oncology Group of Ontario (POGO) has published “Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients” (April 2014). The purpose of this guideline is to provide healthcare providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of antineoplastic administration). >> Quick Review Summary
MASCC Antiemetic Guidelines © 2016 MASCC, Multinational Association for Supportive Care in Cancer™ • All rights reserved worldwide.
For Questions or additional information, contact Executive Director, Aage Schultz, email@example.com